Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib

SIMPLE SUMMARY: Olaparib is a PARP inhibitor that is currently the standard treatment for ovarian cancer. However, its use is largely confined to tumors carrying a mutation in the BRCA1 or BRCA2 genes. Our study sought to identify additional ovarian cancer cell populations sensitive to olaparib. TGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Cai M., Rojas-Alexandre, Mehida, Hanna, Ruth E., Lin, Z. Ping, Ratner, Elena S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417836/
https://www.ncbi.nlm.nih.gov/pubmed/37568736
http://dx.doi.org/10.3390/cancers15153919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417836/
https://www.ncbi.nlm.nih.gov/pubmed/37568736
http://dx.doi.org/10.3390/cancers15153919

Ejemplares similares